The deadline to submit an abstract for short talk and poster presentation consideration has passed. For any questions or issues, please email info@keystonesymposia.org.

While most successful clinical cancer immunotherapy strategies target T cell effector function, there is clear evidence that tumor-associated myeloid cells play a key role in the modulation of tumor growth and tumor immunity, but also tumor response to treatment. Yet targeting tumor-associated myeloid cells has proven difficult and there is a paucity of myeloid drug targets used in clinical oncology. This meeting will focus on myeloid cells with or without antigen presenting cell (APC) function, including dendritic cells, macrophages and monocyte-derived cells which have both the ability to shape the immune microenvironment of tumor lesions and instruct T cell effector and regulatory programs. The  program will highlight the diversity of the tumor-associated APC compartment and describe its cellular and molecular composition and spatial distribution in tumor lesions. We will discuss some of the most promising technology to unravel the diversity of these APC programs as well as the functional contributions of specific APC to cancer progression and response to treatment. Importantly, Finally, this conference will integrate efforts from across academia and industry in order to establish strategies for the development of novel myeloid cell targeted therapies for the clinical treatment of cancer.